BioVie Inc. announced that clinical safety data from the Company's Phase 2 open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, in patients with refractory ascites due to cirrhosis, will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting®? 2023, taking place from November 10-14, 2023 in Boston, MA. The abstract titled "Safety and Tolerability of Continuous Infusion Terlipressin (Biv201) In Patients with Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study" will be presented by Penelope Markham, Ph.D., BioVie's Senior Vice President of Ascites and Strategic Initiatives on November 13 from 1:00 PM - 2:00 PM.

Details of the presented data and conclusions will be announced once the presentations are made public at the conference.